Interview: Qiu Jiazhou – MD Chairman, H-Guard, China
Dr. Qiu, could you please introduce your company, H-Guard, to our international readers? “It is clear that our efforts and investments over the past five years have paid off. Just…
CR Pharmaceutical Group Limited was set up in response to the requirement of the State-Owned Assets Supervision and Administration Commission of the State Council (SASAC) to “create a state-owned pharmaceutical platform” in 2007. It is an integrated enterprise group combining pharmaceutical R&D, manufacturing and production, as well as marketing under one umbrella. Leveraging its strong industrial base leading competitive advantages, CR Pharma is striving to “become the leader in China’s pharmaceutical industry”. In 2013, both turnover and assets of the company exceeded HK$100 billion, and CR Pharma ranked second in terms of overall strength in China’s pharmaceutical industry. On October 28, 2016, China Resources Pharmaceutical Group Limited (3320HK) was officially listed on the Hong Kong Stock Exchange.
CR Pharma owns two grade-1 profit centers, China Resources Sanjiu Medical & Pharmaceutical Co., Ltd., China Resources Double-Crane Pharmaceutical Co., Ltd., as well as famous companies including Shandong Dong-E-E-Jiao Pharmaceutical Co., Ltd., China Resources Zizhu Pharmaceutical Co., Ltd., China Resources Saike Pharmaceutical Co., Ltd., China Anhui World-Best Pharmaceutical Co., Ltd., and China Resources Pien Tze Huang Pharmaceutical Co., Ltd. Among them, CR Sanjiu (000999), CR Double-Crane, and Dong-E-E-Jiao (000423) are A-share pharmaceutical companies listed in China.
In the area of pharmaceutical manufacturing, CR Pharma is involved in natural medicine, Chinese medicine, chemical drugs, biological drugs and nutritional supplements. It ranked number one in the 2011 China Top 100 Pharmaceutical Manufacturing Enterprises, and owns well-known brands including “999”, “Double-Crane”, “Saike”, “Dong-E”, “Zizhu”, and “Yu Ting”.
In terms of retail and distribution, its business covers wholesale distribution of drugs, medical equipment, healthcare products, logistics, distribution, retail and supply chain value-added services. It ranks second among China’s pharmaceutical businesses and is the market leader in the areas of hospital drugs distribution and extended services, and modern logistics and distribution services in China.
CR Pharma possesses abundant and quality R&D resources, and strong independent innovation capabilities. It has established two national research centres for Chinese patent medicine and traditional Chinese gelatine medicine (Ejiao series), and numerous provincial level technology centres, serving as the R&D base for birth control and genital health drugs. It is leading the industry in pharmaceutical preparation and new pharmaceutical controlled-release technologies within China and is world-leading in its core R&D technology in pharmaceutical nucleoside intermediates. Through innovation and collaboration, CR Pharma will continue to focus on providing high-quality and reliable products and services to the public and will strive to become the market leader in China’s pharmaceutical industry.
Dr. Qiu, could you please introduce your company, H-Guard, to our international readers? “It is clear that our efforts and investments over the past five years have paid off. Just…
Simon, you established Glory Medical back in 1998. What was the main rationale behind this significant decision? “We already have operations in Sri Lanka and Pakistan, and are exploring projects…
Dr. Chen Hao is the CEO and founder of the promising startup Imsight, the only company focusing on medical imaging analysis using Artificial Intelligence technology in the Greater Bay Area.…
Alex Wang Yimin, founder and CEO of SONTU Medical Imaging, shares the exciting story of SONTU’s development since 2009, their significant investment into R&D and various international certifications like the…
Dr. Lu Xianping is the founder and now Chairman and CEO of one of China’s few truly innovative biotech companies, ChipScreen BioSciences Co. In this exciting interview, he shares the…
Scott Liang, president of Apex (Guangzhou) Tools and Orthopedics discusses the company’s strong positioning on the Chinese medtech market, current strategic priorities, and what differentiates Apex from its competitors. As…
Dami Qiu, founder and CEO of EMP, shares her personal story of how she decided to establish EMP two decades ago, the market opportunities in ultrasound medical equipment in China,…
In this unique interview, Dr. David Peng, CEO of Medical Excellence International (China), shares the company´s foundations, its key milestones as well as its two unique membership programs. He further…
Sheng Sitong, founder and CEO of gene sequencing device company, Considerin Group (formerly HYK Gene), discusses Considerin’s rapid expansion and the development of precision medicine in China. Mr. Sheng, could…
Yuan Qing, President of the Shenzhen Life Science and Biotechnology Association, shares his insights on the characteristics of the life sciences environment in Shenzhen, the importance of the sectors as…
Guangdong province and neighbouring Hong Kong have long been fundamental to China’s metamorphosis into an economic superpower. Notable as one of the country’s most open and dynamic regions, the Pearl…
One of the more eye-catching and ambitious initiatives to come out of last March’s National People’s Congress, Premier Li Keqiang’s grand vision for the cultivation of a globally competitive cluster…
See our Cookie Privacy Policy Here